Unicycive Therapeutics Inc (UNCY) Stock Analysis

AI analysis of Unicycive Therapeutics Inc (UNCY)

Hold

Unicycive Therapeutics Inc is currently not a strong buy due to its recent performance and technical indicators. The current price is $3.49, which is significantly below its 52-week high of $8.74, indicating a potential for recovery but also substantial risk. The RSI is at 32.171, suggesting the stock is oversold, but the recent 5-day change is -2.51%, reflecting continued downward pressure. The forward P/E ratio is 2.0661, which could indicate potential value, but the company has a negative net income and gross profit in recent quarters, with a net income of -21,525,000 USD in Q4 2024 and -6,447,000 USD in Q2 2025. The main risk is the ongoing FDA issues, as highlighted by the recent news of executives being sued for failing to ensure compliance, which could further impact stock performance.

Valuation Metrics

The current forward P/E ratio for Unicycive Therapeutics Inc (UNCY) is 1.99, compared to its 5-year average forward P/E of 0.45.

Forward P/E

Fair

5Y Average P/E

0.45

Current P/E

1.99

Overvalued

7.03

Undervalued

-6.13

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

-6545.04

Current EV/EBITDA

0.00

Overvalued

23017.88

Undervalued

-36107.96

Forward P/S

Fair

5Y Average P/S

4.06

Current P/S

0.74

Overvalued

15.58

Undervalued

-7.46

Alphio AI Price Scenarios for UNCY

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%UNCY

$5.26

Scenario price

B

Base

Base · 50%UNCY

$4.33

Scenario price

B

Bear

Bear · 25%UNCY

$3.97

Scenario price

Whales holding UNCY

L

Logos Global Management, L.P.

+ HoldingUNCY

+20.59%

3M Return

UNCY FAQ — answered by Alphio AI

Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Unicycive Therapeutics Inc is currently not a strong buy due to its recent performance and technical indicators. The current price is $3.49, which is significantly below its 52-week high of $8.74, indicating a potential for recovery but also substantial risk. The RSI is at 32.171, suggesting the stock is oversold, but the recent 5-day change is -2.51%, reflecting continued downward pressure. The forward P/E ratio is 2.0661, which could indicate potential value, but the company has a negative net income and gross profit in recent quarters, with a net income of -21,525,000 USD in Q4 2024 and -6,447,000 USD in Q2 2025. The main risk is the ongoing FDA issues, as highlighted by the recent news of executives being sued for failing to ensure compliance, which could further impact stock performance.